Aditxt to acquire Appili Therapeutics

2024-04-03

疫苗并购

Preview

来源: Pharmaceutical Technology

The acquisition enhances the portfolio of Aditxt in precision diagnostics and infectious disease treatment. Credit: Gorodenkoff / Shutterstock.com.

Aditxt has announced a definitive agreement under which its subsidiary, Adivir, will acquire complete issued and outstanding Class A common shares of biopharmaceutical company Appili Therapeutics.

The move enhances Aditxt’s portfolio and creates synergies with its existing programmes, particularly in precision diagnostics.

Founded in 2015, Appili developed the Food and Drug Administration-approved LIKMEZ (ATI-1501).

LIKMEZ is a reformulated version of the antibiotic metronidazole that improves patient experience and compliance by making the medication easier to swallow and better tasting.

Appili licensed the manufacturing and commercialisation rights of the product in the US and other selected territories to Saptalis Pharmaceuticals.

See Also:

Forma Therapeutics gets grant for USP30 inhibitor USP30 inhibitor compounds for medical use

Preview

来源: Pharmaceutical Technology

Dyne Therapeutics gets grant for muscle-targeting complex inhibiting DUX4 expression with oligonucleotide payload

Preview

来源: Pharmaceutical Technology

Appili is also advancing ATI-1701, a live attenuated vaccine for Francisella tularensis.

The US Department of Defense has supported the ATI-1701 biodefence programme with $14m non-dilutive funding to progress the vaccine’s development.

Another key asset in Appili’s portfolio is ATI-1801, a topical formulation for cutaneous leishmaniasis.

The product, which contains paromomycin, offers a more patient-friendly treatment option for this painful and disfiguring disease.

The acquisition will aid Aditxt in bolstering its portfolio and integrating precision diagnostics with tailored treatment strategies.

The closure of the acquisition will occur in the third quarter of 2024.

Aditxt co-founder, chairman and CEO Amro Albanna stated: “The acquisition of Appili would represent another step in Aditxt’s journey towards advancing promising innovations in health.

“Our mission is to accelerate some of the most promising health innovations, like those developed by Appili, to reach their full potential and to have a lasting impact.

“By integrating Appili’s proven expertise and diverse portfolio in the infectious disease and biodefence domain, Aditxt can substantially contribute to advancing public health solutions.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构